ORGENESIS INC (ORGS)

US68619K2042 - Common Stock

2.11  -1.13 (-34.84%)

After market: 2.25 +0.14 (+6.64%)

Fundamental Rating

1

Taking everything into account, ORGS scores 1 out of 10 in our fundamental rating. ORGS was compared to 568 industry peers in the Biotechnology industry. ORGS has a bad profitability rating. Also its financial health evaluation is rather negative. ORGS has a valuation in line with the averages, but on the other hand it scores bad on growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

ORGS had negative earnings in the past year.
ORGS had a negative operating cash flow in the past year.
ORGS had negative earnings in 4 of the past 5 years.
ORGS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -124.09%, ORGS is not doing good in the industry: 81.71% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -124.09%
ROE N/A
ROIC N/A
ROA(3y)-142.32%
ROA(5y)-90.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ORGS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

ORGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ORGS has more shares outstanding
ORGS has more shares outstanding than it did 5 years ago.
ORGS has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -12.18, we must say that ORGS is in the distress zone and has some risk of bankruptcy.
ORGS's Altman-Z score of -12.18 is on the low side compared to the rest of the industry. ORGS is outperformed by 79.93% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.18
ROIC/WACCN/A
WACC7.32%

2.3 Liquidity

ORGS has a Current Ratio of 0.07. This is a bad value and indicates that ORGS is not financially healthy enough and could expect problems in meeting its short term obligations.
ORGS's Current ratio of 0.07 is on the low side compared to the rest of the industry. ORGS is outperformed by 98.76% of its industry peers.
A Quick Ratio of 0.07 indicates that ORGS may have some problems paying its short term obligations.
With a Quick ratio value of 0.07, ORGS is not doing good in the industry: 98.76% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.07
Quick Ratio 0.07

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ORGS have decreased strongly by -125.83% in the last year.
ORGS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -98.14%.
Measured over the past years, ORGS shows a very negative growth in Revenue. The Revenue has been decreasing by -50.95% on average per year.
EPS 1Y (TTM)-125.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.75%
Revenue 1Y (TTM)-98.14%
Revenue growth 3Y-58.93%
Revenue growth 5Y-50.95%
Sales Q2Q%-96.47%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y190.48%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year39.76%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ORGS. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 3.39, the valuation of ORGS can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ORGS indicates a rather cheap valuation: ORGS is cheaper than 99.29% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.83. ORGS is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 3.39

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ORGS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ORGS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORGENESIS INC

NASDAQ:ORGS (10/18/2024, 8:00:02 PM)

After market: 2.25 +0.14 (+6.64%)

2.11

-1.13 (-34.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2024-08-13/bmo
Earnings (Next)11-11 2024-11-11/bmo
Inst Owners3.18%
Inst Owner Change-90.25%
Ins Owners790.6%
Ins Owner Change0%
Market Cap10.06M
Analysts82.86
Price Target6.12 (190.05%)
Short Float %0.49%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-98.66%
Min Revenue beat(2)-98.85%
Max Revenue beat(2)-98.46%
Revenue beat(4)0
Avg Revenue beat(4)-98.92%
Min Revenue beat(4)-99.2%
Max Revenue beat(4)-98.46%
Revenue beat(8)2
Avg Revenue beat(8)-49.23%
Revenue beat(12)4
Avg Revenue beat(12)-34.26%
Revenue beat(16)6
Avg Revenue beat(16)-8.82%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.39
P/S 15.2
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.17
EYN/A
EPS(NY)0.62
Fwd EY29.49%
FCF(TTM)-2.63
FCFYN/A
OCF(TTM)-2.52
OCFYN/A
SpS0.14
BVpS-3.25
TBVpS-5.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -124.09%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-142.32%
ROA(5y)-90.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.15%
Cap/Sales 75.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.07
Quick Ratio 0.07
Altman-Z -12.18
F-Score2
WACC7.32%
ROIC/WACCN/A
Cap/Depr(3y)394.92%
Cap/Depr(5y)321.88%
Cap/Sales(3y)150.7%
Cap/Sales(5y)156.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-125.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.75%
EPS Next Y190.48%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-98.14%
Revenue growth 3Y-58.93%
Revenue growth 5Y-50.95%
Sales Q2Q%-96.47%
Revenue Next Year39.76%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-231.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.92%
OCF growth 3YN/A
OCF growth 5YN/A